Human Cardiovascular ELISA Kits
Human F7 (Coagulation Factor VII) ELISA Kit (HUES01901)
- SKU:
- HUES01901
- Product Type:
- ELISA Kit
- Size:
- 96 Assays
- Uniprot:
- P08709
- Sensitivity:
- 37.5pg/mL
- Range:
- 62.5-4000pg/mL
- ELISA Type:
- Sandwich
- Synonyms:
- FVII, Proconvertin, SPCA
- Reactivity:
- Human
- Sample Type:
- Serum, plasma and other biological fluids
- Research Area:
- Cardiovascular
Description
Assay type: | Sandwich |
Format: | 96T |
Assay time: | 4.5h |
Reactivity: | Human |
Detection Method: | Colormetric |
Detection Range: | 62.50-4000 pg/mL |
Sensitivity: | 37.50 pg/mL |
Sample Volume Required Per Well: | 100µL |
Sample Type: | Serum, plasma and other biological fluids |
Specificity: | This kit recognizes Human F7 in samples. No significant cross-reactivity or interference between Human F7 and analogues was observed. |
This ELISA kit uses Sandwich-ELISA as the method. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human F7. Standards or samples are added to the appropriate micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human F7 and Avidin-Horseradish Peroxidase (HRP) conjugate are added to each micro plate well successively and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human F7, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by adding Stop Solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human F7. The concentration of Human F7 in samples can be calculated by comparing the OD of the samples to the standard curve.
UniProt Protein Function: | F7: Initiates the extrinsic pathway of blood coagulation. Serine protease that circulates in the blood in a zymogen form. Factor VII is converted to factor VIIa by factor Xa, factor XIIa, factor IXa, or thrombin by minor proteolysis. In the presence of tissue factor and calcium ions, factor VIIa then converts factor X to factor Xa by limited proteolysis. Factor VIIa will also convert factor IX to factor IXa in the presence of tissue factor and calcium. Defects in F7 are the cause of factor VII deficiency (FA7D). A hemorrhagic disease with variable presentation. The clinical picture can be very severe, with the early occurrence of intracerebral hemorrhages or repeated hemarthroses, or, in contrast, moderate with cutaneous-mucosal hemorrhages (epistaxis, menorrhagia) or hemorrhages provoked by a surgical intervention. Finally, numerous subjects are completely asymptomatic despite very low factor VII levels. Belongs to the peptidase S1 family. 2 isoforms of the human protein are produced by alternative splicing. |
UniProt Protein Details: | Protein type:EC 3. 4. 21. 21; Protease; Apoptosis; Secreted; Secreted, signal peptide; Motility/polarity/chemotaxis Chromosomal Location of Human Ortholog: 13q34 Cellular Component: endoplasmic reticulum lumen; extracellular region; Golgi lumen; plasma membrane Molecular Function:glycoprotein binding; protein binding; serine-type peptidase activity Biological Process: blood coagulation; blood coagulation, extrinsic pathway; ER to Golgi vesicle-mediated transport; peptidyl-glutamic acid carboxylation; positive regulation of cell migration; positive regulation of leukocyte chemotaxis; positive regulation of positive chemotaxis; positive regulation of protein kinase B signaling cascade; signal peptide processing Disease: Factor Vii Deficiency; Myocardial Infarction, Susceptibility To |
NCBI Summary: | This gene encodes coagulation factor VII which is a vitamin K-dependent factor essential for hemostasis. This factor circulates in the blood in a zymogen form, and is converted to an active form by either factor IXa, factor Xa, factor XIIa, or thrombin by minor proteolysis. Upon activation of the factor VII, a heavy chain containing a catalytic domain and a light chain containing 2 EGF-like domains are generated, and two chains are held together by a disulfide bond. In the presence of factor III and calcium ions, the activated factor then further activates the coagulation cascade by converting factor IX to factor IXa and/or factor X to factor Xa. Defects in this gene can cause coagulopathy. Alternative splicing results in multiple transcript variants encoding different isoforms that may undergo similar proteolytic processing to generate mature polypeptides. [provided by RefSeq, Aug 2015] |
UniProt Code: | P08709 |
NCBI GenInfo Identifier: | 119766 |
NCBI Gene ID: | 2155 |
NCBI Accession: | P08709. 1 |
UniProt Secondary Accession: | P08709,Q14339, Q5JVF1, Q5JVF2, Q9UD52, Q9UD53, Q9UD54 B0YJC8, |
UniProt Related Accession: | P08709 |
Molecular Weight: | 49,320 Da |
NCBI Full Name: | Coagulation factor VII |
NCBI Synonym Full Names: | coagulation factor VII |
NCBI Official Symbol: | F7 |
NCBI Official Synonym Symbols: | SPCA |
NCBI Protein Information: | coagulation factor VII |
UniProt Protein Name: | Coagulation factor VII |
UniProt Synonym Protein Names: | Proconvertin; Serum prothrombin conversion accelerator; SPCA |
Protein Family: | F7-1 fimbrial protein |
UniProt Gene Name: | F7 |
UniProt Entry Name: | FA7_HUMAN |
As the OD values of the standard curve may vary according to the conditions of the actual assay performance (e. g. operator, pipetting technique, washing technique or temperature effects), the operator should establish a standard curve for each test. Typical standard curve and data is provided below for reference only.
Concentration (pg/mL) | O.D | Average | Corrected |
4000 | 2.329 2.333 | 2.331 | 2.276 |
2000 | 1.571 1.599 | 1.585 | 1.53 |
1000 | 0.914 0.898 | 0.906 | 0.851 |
500 | 0.449 0.481 | 0.465 | 0.41 |
250 | 0.237 0.211 | 0.224 | 0.169 |
125 | 0.157 0.147 | 0.152 | 0.097 |
62.50 | 0.096 0.114 | 0.105 | 0.05 |
0 | 0.047 0.063 | 0.055 | -- |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, mid range and high level Human F7 were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, mid range and high level Human F7 were tested on 3 different plates, 20 replicates in each plate.
Intra-assay Precision | Inter-assay Precision | |||||
Sample | 1 | 2 | 3 | 1 | 2 | 3 |
n | 20 | 20 | 20 | 20 | 20 | 20 |
Mean (pg/mL) | 219.70 | 356.30 | 1624.50 | 209.50 | 327.10 | 1650.20 |
Standard deviation | 12.50 | 18.50 | 66.60 | 13.00 | 14.40 | 72.60 |
C V (%) | 5.69 | 5.19 | 4.10 | 6.21 | 4.40 | 4.40 |
Recovery
The recovery of Human F7 spiked at three different levels in samples throughout the range of the assay was evaluated in various matrices.
Sample Type | Range (%) | Average Recovery (%) |
Serum (n=5) | 89-100 | 95 |
EDTA plasma (n=5) | 88-99 | 93 |
Cell culture media (n=5) | 89-103 | 96 |
Linearity
Samples were spiked with high concentrations of Human F7 and diluted with Reference Standard & Sample Diluent to produce samples with values within the range of the assay.
Serum (n=5) | EDTA plasma (n=5) | Cell culture media (n=5) | ||
1:2 | Range (%) | 93-107 | 88-98 | 86-99 |
Average (%) | 99 | 93 | 91 | |
1:4 | Range (%) | 101-116 | 84-94 | 96-109 |
Average (%) | 107 | 89 | 101 | |
1:8 | Range (%) | 96-114 | 82-94 | 95-110 |
Average (%) | 104 | 87 | 102 | |
1:16 | Range (%) | 93-108 | 81-93 | 96-108 |
Average (%) | 100 | 86 | 102 |
An unopened kit can be stored at 4°C for 1 month. If the kit is not used within 1 month, store the items separately according to the following conditions once the kit is received.
Item | Specifications | Storage |
Micro ELISA Plate(Dismountable) | 8 wells ×12 strips | -20°C, 6 months |
Reference Standard | 2 vials | |
Concentrated Biotinylated Detection Ab (100×) | 1 vial, 120 µL | |
Concentrated HRP Conjugate (100×) | 1 vial, 120 µL | -20°C(shading light), 6 months |
Reference Standard & Sample Diluent | 1 vial, 20 mL | 4°C, 6 months |
Biotinylated Detection Ab Diluent | 1 vial, 14 mL | |
HRP Conjugate Diluent | 1 vial, 14 mL | |
Concentrated Wash Buffer (25×) | 1 vial, 30 mL | |
Substrate Reagent | 1 vial, 10 mL | 4°C(shading light) |
Stop Solution | 1 vial, 10 mL | 4°C |
Plate Sealer | 5 pieces | |
Product Description | 1 copy | |
Certificate of Analysis | 1 copy |
- Set standard, test sample and control (zero) wells on the pre-coated plate and record theirpositions. It is recommended to measure each standard and sample in duplicate. Note: addall solutions to the bottom of the plate wells while avoiding contact with the well walls. Ensuresolutions do not foam when adding to the wells.
- Aliquot 100 µL of standard solutions into the standard wells.
- Add 100 µL of Sample / Standard dilution buffer into the control (zero) well.
- Add 100 µL of properly diluted sample (serum, plasma, tissue homogenates and otherbiological fluids) into test sample wells.
- Cover the plate with the sealer provided in the kit and incubate for 90 min at 37 °C.
- Aspirate the liquid from each well, do not wash. Immediately add 100 µL of BiotinylatedDetection Ab working solution to each well. Cover the plate with a plate seal and gently mix. Incubate for 1 hour at 37 °C.
- Aspirate or decant the solution from the plate and add 350 µL of wash buffer to each welland incubate for 1-2 minutes at room temperature. Aspirate the solution from each well andclap the plate on absorbent filter paper to dry. Repeat this process 3 times. Note: a microplatewasher can be used in this step and other wash steps.
- Add 100 µL of HRP Conjugate working solution to each well. Cover with a plate seal andincubate for 30 min at 37 °C.
- Aspirate or decant the solution from each well. Repeat the wash process for five times asconducted in step 7.
- Add 90 µL of Substrate Reagent to each well. Cover with a new plate seal and incubate forapproximately 15 min at 37 °C. Protect the plate from light. Note: the reaction time can beshortened or extended according to the actual color change, but not by more than 30min.
- Add 50 µL of Stop Solution to each well. Note: Adding the stop solution should be done inthe same order as the substrate solution.
- Determine the optical density (OD value) of each well immediately with a microplate readerset at 450 nm.